Farmanews.com

Especialidades y enfermedades  
Farmacéuticas

Farmacéuticas. 09 de julio de 2018

Korea finished drug market growth driven by generics

Amsterdam, 9th July 2018: The Korean pharma market is experiencing significant growth in finished drug products, according to CPhI Korea. Over the last 12 months, market conditions have spurred a strong expansion in exports of finished formulations, driven primarily by an expanding domestic generics market.
Acceder
Farmacéuticas. 05 de julio de 2018

CPhI Worldwide opens entries for 15th Annual Pharma Awards

Amsterdam, 2nd July 2018 : CPhI Worldwide – organised by UBM (part of Informa PLC) – announces the opening of the 2018 CPhI Pharma Awards for entries. The industry’s preeminent awards return for a landmark 15th edition, with 17 categories honouring companies and individuals driving the pharma industry forward through innovations, technologies, and strategies.
Acceder
Farmacéuticas. 27 de junio de 2018

Plasticell leads gene therapy manufacturing consortium with Great Ormond Street Hospital and UCL Institute of Child Health

Stevenage, 26 June 2018: Plasticell, a developer of stem cell technologies and therapies, has announced it is leading a consortium of pioneering gene therapy groups at UCL’s Institute of Child Health (ICH) and Great Ormond Street Hospital (GOSH) to develop advanced technologies for the manufacturing of ex vivo gene therapies. The initial focus is on rare inherited disorders of the immune system including Chronic Granulomatous Disease.
Acceder
Farmacéuticas. 27 de junio de 2018

Symcel appoints two new board members to bolster R&D business growth and expansion into the clinical diagnostics market

27 June 2018: Symcel – the company behind the revolutionary cell-based assay tool for real-time cell metabolism measurements, the calScreener™ – has announced the appointment of two new highly experienced board members; Erik Walldén and Stefan Löfås. Both will play a key role in bolstering the full execution of the company’s corporate strategy to grow business in the research market and develop much needed solutions for clinical diagnostics.  
Acceder
Farmacéuticas. 27 de junio de 2018

bioLIVE report predicts PAT, NIRS, continuous bioprocessing, and a ‘technological arms race’ could improve bio process manufacturing efficiency

27 June 2018, Amsterdam: A report from bioLIVE – the new UBM biomanufacturing and bioprocessing event taking place in Madrid (October 9-11, 2018) – has collected findings from a panel of experts to identify a number of potential applications of small molecule expertise that should be applied to the biologics industry. The report forecasts the increasing role outsourcing will play in the bio supply chain and how continuous processing, API and process analytical technology (PAT) expertise will be integral to future growth.
Acceder
Farmacéuticas. 11 de junio de 2018

Attendance rise sees CPhI & P-MEC India 2018 move to Indian capital

Amsterdam, 11 June 2018:  CPhI & P-MEC India (December 10-14, 2018) – organised by UBM – announces that the 12th edition of Asia’s largest Pharma exhibition is moving to the India Expo Mart, New Delhi. The new venue will see the exhibition now hosted in a single venue, bringing it closer to the Indian regulatory and legislative capital. New Delhi is also the country’s main international transport hub and will encourage an increased international attendance. In total, more than 50,000 people from 122 countries are expected, along with nearly 1,500 exhibitors.
Acceder
Farmacéuticas. 05 de junio de 2018

China’s domestic pharma industry driving huge machinery influx at P-MEC China

Amsterdam, 5 June 2018: P-MEC China will be held at the Shanghai New International Expo Center (SNIEC), Shanghai, China, from 20-22 June. The event is seen as an accurate gauge of industry growth potential, and features a large exhibition and several in-depth conferences.
Acceder
Farmacéuticas. 04 de junio de 2018

‘Process innovation needs to be undertaken in early R&D phase’ – predicts ADC Bio

4 June 2018, Wales: ADC Biotechnology (ADC Bio) predicts that the next crucial phase of innovation to optimise and streamline production processes of ADCs will be designed at the clinical development stage by specialist, ADC focused service providers. At present, a number of the larger CDMOsare focused solely on commercial scale ADC production and lack both the bandwidth and motivation for innovative manufacturing methods.
Acceder

Subir  

Subir notas de prensa y convocatorias

Próximas convocatorias   

No hay próximas convocatorias
Ver todas

Especialidades  

Busca notas de prensa por especialidad médica o enfermedad.



Ver todas

Archivo  

Busca notas de prensa por su fecha de edición.

  Selecciona el año


Copyright © 2018, Farmavet, S.L. Todos los derechos reservados.